No Data
Australian and Chinese Endoscopy: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
Auhua Endoscopy (688212.SH): First buyback of 0.0991 million shares.
Gelonghui reported on February 26 that Australia Huanuo Medical (688212.SH) announced that on February 26, 2025, the company conducted its first share buyback by centralized bidding, repurchasing 99,050 shares, accounting for 0.07% of the total share capital of 134,587,250 shares. The highest transaction price was 40.00 yuan/share, the lowest price was 39.85 yuan/share, and the total amount paid was 3,955,494.08 yuan (excluding stamp duty, transaction commissions, and other transaction costs).
Aohua Endoscopy (688212.SH): The net income for the year 2024 is 21.3218 million yuan, a decrease of 63.15% year-on-year.
Aohua Endoscopy (688212.SH) released the 2024 performance preliminary report, during the reporting period the company achieved revenue of 7...
Shanghai Aohua Photoelectricity Endoscope (SHSE:688212) May Have Issues Allocating Its Capital
Guosen: Focus on AI + Medical, high-quality innovation, and value symbols with stable performance.
Guosen remains bullish on companies with differentiated innovation capabilities and overseas potential.
There's Been No Shortage Of Growth Recently For Shanghai Aohua Photoelectricity Endoscope's (SHSE:688212) Returns On Capital
